King's College London

Research portal

No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease

Research output: Contribution to journalArticle

Justin Tao Wen Chiam, Katie Lunnon, Nicola Voyle, Petra Proitsi, Giovanni Coppola, Daniel Geschwind, Sally Nelson, Caroline Johnston, Hilkka Soininen, Iwona Kłoszewska, Patrizia Mecocci, Magda Tsolaki, Bruno Vellas, Angela Hodges, Simon Lovestone, Stephen Newhouse, Richard James Butler Dobson, Steven John Kiddle, Martina Sattlecker

Original languageEnglish
Pages (from-to)741-750
Number of pages10
Issue number3
StatePublished - 3 Aug 2015


King's Authors


BACKGROUND: There is an urgent need to discover Alzheimer's disease (AD) biomarkers that are both easily measured and reliable. Research into blood-based biomarkers for AD using transcriptomics and proteomics has been an attractive and promising area of research. However, to date researchers have not looked into the possibility of AD medication being a confounding factor in these studies.

OBJECTIVE: This study explored whether acetylcholinesterase inhibitors (AChEIs), the main class of AD medication, are a confounding factor in AD blood biomarker studies.

METHODS: The most promising blood transcriptomic and proteomic biomarkers from two recent studies were analyzed to determine if they were differentially expressed between AD subjects on AChEIs and subjects that were not.

RESULTS: None of the gene or protein biomarkers analyzed were found to be significantly altered between subjects in either group.

CONCLUSION: This study found no evidence that AChEIs are a confounding factor in these published AD blood biomarker studies. Further work is needed to confirm that this is also the case for other proposed biomarkers.

Download statistics

No data available

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454